SUPN

28.6100.92%
SA

Stuart Anthony Kingsley

Independent Non-Executive Chair

Mr. Stuart Anthony Kingsley, MBA, also known as Tony, is Chief Executive Officer of CereVasc, Inc. from September 15, 2026. He is Chairman of the Board of Supernus Pharmaceuticals, Inc. from 2026. He is Independent Non-Executive Director of Supernus, Inc. (Earlier known as Indivior Pharmaceuticals, Inc.) from July 1, 2025 and serves as its Independent Non-Executive Chair since November 2, 2026. He served as Chief Executive Officer of Stablix, Inc. since February 2022 until September 2025 and served as its Director until September 2025. Mr. Kingsley served as Chief Executive Officer and President of Scholar Rock, Inc. since August 1, 2020 until August 2021 and served as its Director since May 2020 until August 2021. He served as a Director of Scholar Rock Holding Corporation since May 2020 until August 2021. Mr. Kingsley served as President and Chief Executive Officer of Scholar Rock Holding Corporation since August 1, 2020 until August 2021. He served as the President, Chief Executive Officer & Board Director at TARIS BioMedical, Inc. since January 2019, guiding the company through its acquisition by Janssen Pharmaceuticals. Mr. Kingsley was the President and Chief Operating Officer of The Medicines Company since May 2016 until December 29, 2017. Mr. Kingsley served as Executive Vice President of Global Commercial Operations at Biogen Idec Ltd. Mr. Kingsley served as an Executive Vice President of Global Commercial Operations at Biogen Inc. (alternate name, Biogen Idec Inc.) from November 2011 to October 2015 and served as its Senior Vice President of US Commercial Operations from January 2010 to November 7, 2011. He served as the President of GYN Surgical Products of Hologic, Inc. since October 2007 and served as its Senior Vice President and General Manager of GYN Surgical Products from October 2007 to November 2009. He joined Hologic, Inc. in October 2007 in connection with Hologic, Inc.’s merger with Cytyc. Mr. Kingsley served as the President of Diagnostic Products division of Cytyc Corporation from July 2006 to October 2007 and its Senior Vice President since July 2006, where he ran the U.S. commercial operations for the ThinPrep® System, the ThinPrep Imaging System and FullTerm®, the Fetal Fibronectin Test, as well as global functions in operations, product development and customer service. Mr. Kingsley was a Partner and Associate of McKinsey & Company, Inc. from November 1991 to July 2006. He was a Director of Proteon Therapeutics, Inc. since October 19, 2015 until April 15, 2019. He served as a Director of Protara Therapeutics, Inc. He serves as Member of the Board at Third Wave Technologies, Inc. Mr. Kingsley holds an MBA from the Harvard Graduate School of Business Administration from Harvard Business School. and a BA from Dartmouth College.

Positions